Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2018

Open Access 01-12-2018 | Research

Genetic sequence characterization and naturally acquired immune response to Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2)

Authors: Najara C. Bittencourt, Juliana A. Leite, Ana Beatriz I. E. Silva, Tamirys S. Pimenta, João Luiz Silva-Filho, Gustavo C. Cassiano, Stefanie C. P. Lopes, Joao C. K. dos-Santos, Catarina Bourgard, Helder I. Nakaya, Ana Maria Revorêdo da Silva Ventura, Marcus V. G. Lacerda, Marcelo U. Ferreira, Ricardo L. D. Machado, Letusa Albrecht, Fabio T. M. Costa

Published in: Malaria Journal | Issue 1/2018

Login to get access

Abstract

Background

The genetic diversity of malaria antigens often results in allele variant-specific immunity, imposing a great challenge to vaccine development. Rhoptry Neck Protein 2 (PvRON2) is a blood-stage antigen that plays a key role during the erythrocyte invasion of Plasmodium vivax. This study investigates the genetic diversity of PvRON2 and the naturally acquired immune response to P. vivax isolates.

Results

Here, the genetic diversity of PvRON21828–2080 and the naturally acquired humoral immune response against PvRON21828–2080 in infected and non-infected individuals from a vivax malaria endemic area in Brazil was reported. The diversity analysis of PvRON21828–2080 revealed that the protein is conserved in isolates in Brazil and worldwide. A total of 18 (19%) patients had IgG antibodies to PvRON21828–2080. Additionally, the analysis of the antibody response in individuals who were not acutely infected with malaria, but had been infected with malaria in the past indicated that 32 patients (33%) exhibited an IgG immune response against PvRON2.

Conclusions

PvRON2 was conserved among the studied isolates. The presence of naturally acquired antibodies to this protein in the absence of the disease suggests that PvRON2 induces a long-term antibody response. These results indicate that PvRON2 is a potential malaria vaccine candidate.
Appendix
Available only for authorised users
Literature
1.
Alexander DL, Mital J, Ward GE, Bradley P, Boothroyd JC. Identification of the moving junction complex of Toxoplasma gondii: a collaboration between distinct secretory organelles. PLoS Pathog. 2005;1:e17.CrossRef
2.
Cao J, Kaneko O, Thongkukiatkul A, Tachibana M, Otsuki H, Gao Q, et al. Rhoptry neck protein RON2 forms a complex with microneme protein AMA1 in Plasmodium falciparum merozoites. Parasitol Int. 2009;58:29–35.CrossRef
3.
Arévalo-Pinzón G, Curtidor H, Patiño LC, Patarroyo MA. PvRON2, a new Plasmodium vivax rhoptry neck antigen. Malar J. 2011;10:60.CrossRef
4.
Ord RL, Rodriguez M, Cursino-Santos JR, Hong H, Singh M, Gray J, et al. Identification and characterization of the rhoptry neck protein 2 in Babesia divergens and Babesia microti. Infect Immun. 2016;84:1574–84.CrossRef
5.
Giovannini D, Späth S, Lacroix C, Perazzi A, Bargieri D, Lagal V, et al. Independent roles of apical membrane antigen 1 and rhoptry neck proteins during host cell invasion by apicomplexa. Cell Host Microbe. 2011;10:591–602.CrossRef
6.
Srinivasan P, Yasgar A, Luci DK, Beatty WL, Hu X, Andersen J, et al. Disrupting malaria parasite AMA1-RON2 interaction with a small molecule prevents erythrocyte invasion. Nat Commun. 2013;4:2261.CrossRef
7.
Srinivasan P, Beatty WL, Diouf A, Herrera R, Ambroggio X, Moch JK, et al. Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proc Natl Acad Sci USA. 2011;108:13275–80.CrossRef
8.
Tonkin ML, Roques M, Lamarque MH, Pugnière M, Douguet D, Crawford J, et al. Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide. Science. 2011;333:463–7.CrossRef
9.
Richards JS, Beeson JG. The future for blood-stage vaccines against malaria. Immunol Cell Biol. 2009;87:377–90.CrossRef
10.
de Cassan SC, Shakri AR, Llewellyn D, Elias SC, Cho JS, Goodman AL, et al. Preclinical assessment of viral vectored and protein vaccines targeting the duffy-binding protein region II of Plasmodium vivax. Front Immunol. 2015;6:348.CrossRef
11.
Vicentin EC, Françoso KS, Rocha MV, Iourtov D, Dos Santos FL, Kubrusly FS, et al. Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast. Infect Immun. 2014;82:1296–307.CrossRef
12.
Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, et al. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium. Vaccine. 2010;28:2818–26.CrossRef
13.
Mueller I, Shakri AR, Chitnis CE. Development of vaccines for Plasmodium vivax malaria. Vaccine. 2015;33:7489–95.CrossRef
14.
Barry AE, Arnott A. Strategies for designing and monitoring malaria vaccines targeting diverse antigens. Front Immunol. 2014;5:359.CrossRef
15.
Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, Escalante AA, et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med. 2009;1:2ra5.CrossRef
16.
Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med. 1998;4:358–60.CrossRef
17.
Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 2006;28:51–60.CrossRef
18.
Mueller I, Galinski MR, Tsuboi T, Arevalo-Herrera M, Collins WE, King CL. Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targets. Adv Parasitol. 2013;81:77–131.CrossRef
19.
Marsh K, Howard RJ. Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants. Science. 1986;231:150–3.CrossRef
20.
Snounou G, Singh B. Nested PCR analysis of Plasmodium parasites. Methods Mol Med. 2002;72:189–203.PubMed
21.
Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990;276:172–4.CrossRef
22.
Moll K, Ljungström I, Perlmann H, Scherf A, Wahlgren M. Methods in malaria research. 5th ed. Manassas: MR4/ATCC; 2008.
23.
Aurrecoechea C, Brestelli J, Brunk BP, Dommer J, Fischer S, Gajria B, et al. PlasmoDB: a functional genomic database for malaria parasites. Nucleic Acids Res. 2009;37(Database issue):D539–43.CrossRef
24.
Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. GenBank. Nucleic Acids Res. 2005;33(Database issue):D34–8.CrossRef
25.
Sambrook J, Russell DW. Preparation and transformation of competent E. coli using calcium chloride. CSH Protoc. 2006;2006:1.
26.
Ferreira MU, Kaneko O, Kimura M, Liu Q, Kawamoto F, Tanabe K. Allelic diversity at the merozoite surface protein-1 (MSP-1) locus in natural Plasmodium falciparum populations: a brief overview. Mem Inst Oswaldo Cruz. 1998;93:631–8.CrossRef
27.
Cole-Tobian J, King CL. Diversity and natural selection in Plasmodium vivax Duffy binding protein gene. Mol Biochem Parasitol. 2003;127:121–32.CrossRef
28.
Escalante AA, Grebert HM, Chaiyaroj SC, Magris M, Biswas S, Nahlen BL, et al. Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum. X. Asembo Bay Cohort Project. Mol Biochem Parasitol. 2001;113:279–87.CrossRef
29.
Moon SU, Na BK, Kang JM, Kim JY, Cho SH, Park YK, et al. Genetic polymorphism and effect of natural selection at domain I of apical membrane antigen-1 (AMA-1) in Plasmodium vivax isolates from Myanmar. Acta Trop. 2010;114:71–5.CrossRef
30.
Dias S, Wickramarachchi T, Sahabandu I, Escalante AA, Udagama PV. Population genetic structure of the Plasmodium vivax circumsporozoite protein (Pvcsp) in Sri Lanka. Gene. 2013;518:381–7.CrossRef
31.
Zakeri S, Abouie Mehrizi A, Djadid ND, Snounou G. Circumsporozoite protein gene diversity among temperate and tropical Plasmodium vivax isolates from Iran. Trop Med Int Health. 2006;11:729–37.CrossRef
32.
de Sousa TN, Carvalho LH, de Brito CFA. Worldwide genetic variability of the Duffy binding protein: insights into Plasmodium vivax vaccine development. PLoS ONE. 2011;6:e22944.CrossRef
33.
González-Cerón L, Cerritos R, Corzo-Mancilla J, Santillán F. Diversity and evolutionary genetics of the three major Plasmodium vivax merozoite genes participating in reticulocyte invasion in southern Mexico. Parasit Vectors. 2015;8:651.CrossRef
34.
Gutierrez A, Vicini J, Patarroyo ME, Murillo LA, Patarroyo MA. Plasmodium vivax: polymorphism in the merozoite surface protein 1 gene from wild Colombian isolates. Exp Parasitol. 2000;95:215–9.CrossRef
35.
Prajapati SK, Joshi H, Valecha N. Plasmodium vivax merozoite surface protein-3 alpha: a high-resolution marker for genetic diversity studies. J Vector Borne Dis. 2010;47:85–90.PubMed
36.
Putaporntip C, Jongwutiwes S, Ferreira MU, Kanbara H, Udomsangpetch R, Cui L. Limited global diversity of the Plasmodium vivax merozoite surface protein 4 gene. Infect Genet Evol. 2009;9:821–6.CrossRef
37.
Gomez A, Suarez CF, Martinez P, Saravia C, Patarroyo MA. High polymorphism in Plasmodium vivax merozoite surface protein-5 (MSP5). Parasitology. 2006;133(Pt 6):661–72.CrossRef
38.
Garzón-Ospina D, López C, Forero-Rodríguez J, Patarroyo MA. Genetic diversity and selection in three Plasmodium vivax merozoite surface protein 7 (Pvmsp-7) genes in a Colombian population. PLoS ONE. 2012;7:e45962.CrossRef
39.
Chenet SM, Pacheco MA, Bacon DJ, Collins WE, Barnwell JW, Escalante AA. The evolution and diversity of a low complexity vaccine candidate, merozoite surface protein 9 (MSP-9), in Plasmodium vivax and closely related species. Infect Genet Evol. 2013;20:239–48.CrossRef
40.
Garzon-Ospina D, Romero-Murillo L, Patarroyo MA. Limited genetic polymorphism of the Plasmodium vivax low molecular weight rhoptry protein complex in the Colombian population. Infect Genet Evol. 2010;10:261–7.CrossRef
41.
Vallejo AF, Martinez NL, Tobon A, Alger J, Lacerda MV, Kajava AV, et al. Global genetic diversity of the Plasmodium vivax transmission-blocking vaccine candidate Pvs48/45. Malar J. 2016;15:202.CrossRef
42.
Mehrizi AA, Dodangeh F, Zakeri S, Djadid ND. Worldwide population genetic analysis and natural selection in the Plasmodium vivax generative cell specific 1 (PvGCS1) as a transmission-blocking vaccine candidate. Infect Genet Evol. 2016;43:50–7.CrossRef
43.
Putaporntip C, Jongwutiwes S, Tia T, Ferreira MU, Kanbara H, Tanabe K. Diversity in the thrombospondin-related adhesive protein gene (TRAP) of Plasmodium vivax. Gene. 2001;268:97–104.CrossRef
44.
Rodrigues-da-Silva RN, Soares IF, Lopez-Camacho C, da Silva JHM, Perce-da-Silva DS, Têva A, et al. Cell-Traversal protein for ookinetes and sporozoites: naturally acquired humoral immune response and B-Cell epitope mapping in Brazilian amazon inhabitants. Front Immunol. 2017;8:77.CrossRef
45.
Arnott A, Mueller I, Ramsland PA, Siba PM, Reeder JC, Barry AE. Global population structure of the genes encoding the malaria vaccine candidate, Plasmodium vivax apical membrane antigen 1 (PvAMA1). PLoS Negl Trop Dis. 2013;7:e2506.CrossRef
46.
Arnott A, Wapling J, Mueller I, Ramsland PA, Siba PM, Reeder JC, et al. Distinct patterns of diversity, population structure and evolution in the AMA1 genes of sympatric Plasmodium falciparum and Plasmodium vivax populations of Papua New Guinea from an area of similarly high transmission. Malar J. 2014;13:233.CrossRef
47.
Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML, Collins CR, Withers-Martinez C, Hackett F, et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science. 2005;308:408–11.CrossRef
48.
Garg S, Alam MT, Das MK, Dev V, Kumar A, Dash AP, et al. Sequence diversity and natural selection at domain I of the apical membrane antigen 1 among Indian Plasmodium falciparum populations. Malar J. 2007;6:154.CrossRef
49.
Cortés A, Mellombo M, Mueller I, Benet A, Reeder JC, Anders RF. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun. 2003;71:1416–26.CrossRef
50.
Thakur A, Alam MT, Bora H, Kaur P, Sharma YD. Plasmodium vivax: sequence polymorphism and effect of natural selection at apical membrane antigen 1 (PvAMA1) among Indian population. Gene. 2008;419:35–42.CrossRef
51.
Gunasekera AM, Wickramarachchi T, Neafsey DE, Ganguli I, Perera L, Premaratne PH, et al. Genetic diversity and selection at the Plasmodium vivax apical membrane antigen-1 (PvAMA-1) locus in a Sri Lankan population. Mol Biol Evol. 2007;24:939–47.CrossRef
52.
Vulliez-Le Normand B, Saul FA, Hoos S, Faber BW, Bentley GA. Cross-reactivity between apical membrane antigen 1 and rhoptry neck protein 2 in P. vivax and P. falciparum: a structural and binding study. PLoS ONE. 2017;12:e0183198.CrossRef
53.
Vulliez-Le Normand B, Tonkin ML, Lamarque MH, Langer S, Hoos S, Roques M, et al. Structural and functional insights into the malaria parasite moving junction complex. PLoS Pathog. 2012;8:e1002755.CrossRef
54.
Bermúdez M, Arévalo-Pinzón G, Rubio L, Chaloin O, Muller S, Curtidor H, et al. Receptor–ligand and parasite protein–protein interactions in Plasmodium vivax: analysing rhoptry neck proteins 2 and 4. Cell Microbiol. 2018;20:e12835.CrossRef
55.
Collins CR, Withers-Martinez C, Hackett F, Blackman MJ. An inhibitory antibody blocks interactions between components of the malarial invasion machinery. PLoS Pathog. 2009;5:e1000273.CrossRef
56.
Garzón-Ospina D, Forero-Rodríguez J, Patarroyo MA. Inferring natural selection signals in Plasmodium vivax-encoded proteins having a potential role in merozoite invasion. Infect Genet Evol. 2015;33:182–8.CrossRef
57.
Tang J, Dai Y, Zhang H, Culleton RL, Liu Y, Zhao S, et al. Positive diversifying selection on Plasmodium vivax RON2 protein. Parasitology. 2012;139:709–15.CrossRef
58.
Buitrago SP, Garzón-Ospina D, Patarroyo MA. Size polymorphism and low sequence diversity in the locus encoding the Plasmodium vivax rhoptry neck protein 4 (PvRON4) in Colombian isolates. Malar J. 2016;15:501.CrossRef
59.
Marques AC. Human migration and the spread of malaria in Brazil. Parasitol Today. 1987;3:166–70.CrossRef
60.
Ferreira MU, Castro MC. Challenges for malaria elimination in Brazil. Malar J. 2016;15:284.CrossRef
61.
Recht J, Siqueira AM, Monteiro WM, Herrera SM, Herrera S, Lacerda MVG. Malaria in Brazil, Colombia, Peru and Venezuela: current challenges in malaria control and elimination. Malar J. 2017;16:273.CrossRef
62.
Rouhani M, Zakeri S, Mehrizi AA, Djadid ND. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran. Malar J. 2015;14:58.CrossRef
63.
Weaver R, Reiling L, Feng G, Drew DR, Mueller I, Siba PM, et al. The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria. Sci Rep. 2016;6:33094.CrossRef
64.
Taylor RR, Allen SJ, Greenwood BM, Riley EM. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg. 1998;58:406–13.CrossRef
65.
Baird JK. Age-dependent characteristics of protection v susceptibility to Plasmodium falciparum. Ann Trop Med Parasitol. 1998;92:367–90.CrossRef
66.
Amoah LE, Nuvor SV, Obboh EK, Acquah FK, Asare K, Singh SK, et al. Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana. Parasit Vectors. 2017;10:395.CrossRef
67.
Patel P, Bharti PK, Bansal D, Raman RK, Mohapatra PK, Sehgal R, et al. Genetic diversity and antibody responses against Plasmodium falciparum vaccine candidate genes from Chhattisgarh, Central India: implication for vaccine development. PLoS ONE. 2017;12:e0182674.CrossRef
68.
Khosravi A, Hommel M, Sayemiri K. Age-dependent antibody response to Plasmodium falciparum merozoite surface protein 2 (MSP-2). Parasite Immunol. 2011;33:145–57.CrossRef
69.
Yeom JS, Kim ES, Lim KJ, Oh JH, Sohn MJ, Yoo SB, et al. Naturally acquired IgM antibody response to the C-terminal region of the merozoite surface protein 1 of Plasmodium vivax in Korea: use for serodiagnosis of vivax malaria. J Parasitol. 2008;94:1410–4.CrossRef
70.
López C, Yepes-Pérez Y, Díaz-Arévalo D, Patarroyo ME, Patarroyo MA. The in vitro antigenicity of Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2) B- and T-epitopes selected by HLA-DRB1 binding profile. Front Cell Infect Microbiol. 2018;8:156.CrossRef
71.
Zeyrek FY, Kurcer MA, Zeyrek D, Simsek Z. Parasite density and serum cytokine levels in Plasmodium vivax malaria in Turkey. Parasite Immunol. 2006;28:201–7.CrossRef
72.
Gonçalves RM, Scopel KK, Bastos MS, Ferreira MU. Cytokine balance in human malaria: does Plasmodium vivax elicit more inflammatory responses than Plasmodium falciparum? PLoS ONE. 2012;7:e44394.CrossRef
73.
Gentil F, Bargieri DY, Leite JA, Francoso KS, Patricio MB, Espindola NM, et al. A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice. Vaccine. 2010;28:6183–90.CrossRef
74.
Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun. 2002;70:6961–7.CrossRef
75.
Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE. 2009;4:e5254.CrossRef
76.
Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med. 2011;365:1004–13.CrossRef
77.
Srinivasan P, Ekanem E, Diouf A, Tonkin ML, Miura K, Boulanger MJ, et al. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc Natl Acad Sci USA. 2014;111:10311–6.CrossRef
78.
Srinivasan P, Baldeviano GC, Miura K, Diouf A, Ventocilla JA, Leiva KP, et al. A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection. NPJ Vaccines. 2017;2:e14.CrossRef
79.
Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJ, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol. 2013;191:795–809.CrossRef
Metadata
Title
Genetic sequence characterization and naturally acquired immune response to Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2)
Authors
Najara C. Bittencourt
Juliana A. Leite
Ana Beatriz I. E. Silva
Tamirys S. Pimenta
João Luiz Silva-Filho
Gustavo C. Cassiano
Stefanie C. P. Lopes
Joao C. K. dos-Santos
Catarina Bourgard
Helder I. Nakaya
Ana Maria Revorêdo da Silva Ventura
Marcus V. G. Lacerda
Marcelo U. Ferreira
Ricardo L. D. Machado
Letusa Albrecht
Fabio T. M. Costa
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2018
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-018-2543-7

Other articles of this Issue 1/2018

Malaria Journal 1/2018 Go to the issue

Research

Malaria incidence and prevalence during the first year of life in Nanoro, Burkina Faso: a birth-cohort study

Research

Housing gaps, mosquitoes and public viewpoints: a mixed methods assessment of relationships between house characteristics, malaria vector biting risk and community perspectives in rural Tanzania

Research

Isolation and characterization of malaria PfHRP2 specific VNAR antibody fragments from immunized shark phage display library

Research

Spatio-temporal dynamic of malaria in Ouagadougou, Burkina Faso, 2011–2015

Research

Intermittent screening and treatment or intermittent preventive treatment compared to current policy of single screening and treatment for the prevention of malaria in pregnancy in Eastern Indonesia: acceptability among health providers and pregnant women

Research

Genetic diversity and natural selection of Plasmodium knowlesi merozoite surface protein 1 paralog gene in Malaysia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits